Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026
NOVATO, Calif., July 13, 2026 /PRNewswire/ -- Lighthouse Pharmaceuticals today announced new analyses from the Phase 2/3 GAIN trial demonstrating that atuzaginstat, a gingipain inhibitor targeting Porphyromonas gingivalis (Pg), was associated with benefits in several neuropsychiatric...
NOVATO, Calif., July 13, 2026 /PRNewswire/ -- Lighthouse Pharmaceuticals today announced new analyses from the Phase 2/3 GAIN trial demonstrating that atuzaginstat, a gingipain inhibitor targeting Porphyromonas gingivalis (Pg), was associated with benefits in several neuropsychiatric...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.